Changes in haematological parameters and serum beta-2-microglobulin levels in CD4+ T-cells-stratified Nigerian HIV patients
DOI:
https://doi.org/10.15584/ejcem.2021.1.5Keywords:
beta-2-microglobulin, CD4+ T-cells count, haemocytometry, HIV, lymphopaeniaAbstract
Introduction. Reports have shown that there is a rise in beta-2-microglobulin (β2M) concentration in patients with HIV infection and that the degree of elevation correlates well with the extent of disease burden and could be an independent prognostic marker for death. However, there is the dearth of information on the interplay between alteration in haematological profile, a common cause of morbidity and mortality in HIV, and β2M.
Aim. Changes in selected haematological parameters and β2M in Nigerian HIV patients stratified based on CD4+ T-cells counts were thus assessed in this study.
Material and methods. Forty-eight asymptomatic, drug naïve HIV patients were enrolled into this cross-sectional study. Haemoglobin concentration (Hb), packed cell volume (PCV), total and differential white blood cell count, platelet count and CD4+ T-cells count were determined using standard methods while serum levels of β2M were determined using ELISA. Thereafter, the patients were stratified into three groups based on the CD4+ T-cells count.
Results. Hb and lymphocyte counts increased with increasing CD4+ T-cells count. In contrast, neutrophils percentage, MCV and MCH reduced with increasing CD4+ T-cells count. The mean lymphocytes percentage was significantly higher while the mean neutrophils percentage was significantly lower in patients with CD4+ T-cells count of 500–800 cells/μl compared with the patients with CD4+ T-cells count <200 cells/μl. Similarly, the mean MCV was significantly lower in patients with CD4+ T-cells count of 500–800 cells/μl compared with patients with CD4+ T-cells count of 200–499 cells/μl and patients with CD4+ T-cells count <200 cells/μl. β2M had significant positive correlation with WBC and neutrophils percentage but had a significant negative correlation with lymphocytes percentage and MCH in patients with CD4+ T-cells count <200 cells/μl. However, β2M had significant positive correlation with PCV, Hb, monocytes and morphology in patients with CD4+ T-cells count of 500–800 cells/μl.
Conclusion. It could be concluded from this study that HIV infection is associated with alteration in haematological profile and the alteration is CD4+ T-cells count-dependent. Also, elevation in β2M concentration appears to be a marker of lymphopaenia in patients with low CD4+ T-cells count.
Downloads
References
Pietrzak JRT, Maharaj Z, Mokete L, Sikhauli N. Human immunodeficiency virus in total hip arthroplasty. EFORT Open Rev. 2020;5(3):164-171.
Cosby CD. Hematologic disorders associated with human immunodeficiency virus and AIDS. J Infus Nurs. 2007;30(1):22-32.
Kaplan JE, Hu DJ, Holmes KK, Jaffe HW, Masur H, De Cock KM. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. The Am J Trop Med Hyg. 1996;55(1):1-11.
Rubaihayo J, Tumwesigye NM, Konde-Lule J. Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda. BMC Infect Dis. 2015;15:187.
Chauveau L, Donahue DA, Monel B, et al. HIV fusion in dendritic cells occurs mainly at the surface and is limited by low CD4 levels. J Virol. 2017;91(21):e01248-17.
Munyazesa E, Emile I, Mutimura E, et al. Assessment of haematological parameters in HIV-infected and uninfected Rwandan women: a cross-sectional study. BMJ Open. 2012;2:e001600
Durandt C, Potgieter JC, Mellet J, et al. HIV and haematopoiesis. S Afr Med J. 2019;109(8b):40-45.
Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(1):29-33.
Shen Y, Wang J, Wang Z, et al. A cross-sectional study of leukopenia and thrombocytopenia among Chinese adults with newly diagnosed HIV/AIDS. Bioscience Trends. 2015;9(2):91-96.
Shah I, Murthy A. Bone marrow abnormalities in HIV infected children, report of three cases and review of the literature. J Res Med Sci. 2014;19(2):181-183.
Helbert M. T-cell receptor variable gene products and early HIV-1 infection. Lancet. 1992;339(8804):1299-1300.
Helbert M, Breuer J. Monitoring patients with HIV disease. J Clin Pathol. 2000;53(4):266-272.
Fuchs D, Krämer A, Reibnegger G, et al. Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection. Infection. 1991;19(2):98-102.
Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chinese Medical Journal. 2016;129(4):448-455.
Shi C, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discovery Today. 2009;14(1-2):25-30.
Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron. 2000;85(3):207-214.
Balint E, Sprague SM. Beta(2)-microglobulin and bone cell metabolism. Nephrol Dial Transplant. 2001;16(6):1108-1111.
Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007;110(8):3028-3035.
Prizment AE, Linabery AM, Lutsey PL, et al. Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC). Cancer Epidemiol Biomarkers Prev. 2016;25(4):657-664.
Mendy J, Togun T, Owolabi O, Donkor S, Ota MO, Sutherland JS. C-reactive protein, Neopterin and Beta2 microglobulin levels pre and post TB treatment in The Gambia. BMC Infect Dis. 2016;16:115.
Moodley D, Coovadia HM, Bobat RA. beta 2-Microglobulin and CD4/CD8 ratio as HIV-1 markers of maternal transmissibility, neonatal infection and disease progression. Ann Trop Paediatr. 1996;16(2):155-160.
Chitra P, Bakthavatsalam B, Palvannan T. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy. Clin Chim Acta. 2011;412(11-12):1151-1154.
Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322(3):166-172.
Mocroft A, Johnson MA, Sabin CA, Bofill M, Janossy G, Phillips AN. The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Epidemiol Infect. 1997;118(3):259-266.
Olaniyi JA, Arinola OG. Essential trace elements and antioxidants status in relation to severity of HIV in Nigerian patients. Med Princ Pract. 2007;16(6):420-425.
Onifade AA, Emeka GJ, Olaniyi JA, Adeyanju AS, Ojerinde AO, Aiku AO. Non-reliability of Beta-2 Microglobulin and Neopterin as Short-term Immunological Markers of HIV Progression. Afr J Biomed Res. 2016;19:205-212.
Organization WH. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance: African Region. World Health Organization, 2005.
Anastos K, Shi Q, French AL, et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35(4):383-392.
Bhardwaj S, Almaeen A, Ahmed Wani F, Thirunavukkarasu A. Hematologic derangements in HIV/AIDS patients and their relationship with the CD4 counts: a cross-sectional study. Int J Clin Exp Pathol. 2020;13(4):756-763.
Vishnu P, Aboulafia DM. Haematological manifestations of human immune deficiency virus infection. Br J Haematol. 2015;171(5):695-709.
De Santis GC, Brunetta DM, Vilar FC, et al. Hematological abnormalities in HIV-infected patients. Int J Infect Dis. 2011;15(12):e808-811.
Mata-Marín JA, Gaytán-Martínez JE, Martínez-Martínez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M. Risk factors and correlates for anemia in HIV treatment-naïve infected patients: a cross-sectional analytical study. BMC Res Notes. 2010;3:230.
Aboulafia DM, Mitsuyasu RT. Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am. 1991;5(2):195-214.
Obirikorang C, Yeboah FA. Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting. J Biomed Sci. 2009;16(1):102.
Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front Physiol. 2018;9:113.
Hensley-McBain T, Klatt NR. The Dual Role of Neutrophils in HIV Infection. Current HIV/AIDS Reports. 2018;15(1):1-10.
Musubire AK, Meya DB, Rhein J, Meintjes G, Bohjanen PR, Nuwagira E et al. Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality. PLoS One 2018;13(12):e0209337.
Obirikorang C, Quaye L, Acheampong I. Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings. BMC Infect Dis. 2012;12:128.
Calis JC, Phiri KS, Faragher EB, Brabin BJ, Bates I, Cuevas LE, et al. Severe anemia in Malawian children. N Engl J Med. 2008;358(9):888-899.
Janus J, Moerschel SK. Evaluation of anemia in children. Am Fam Physician. 2010;81(12):1462-1471.
Hsieh YP, Chang CC, Kor CT, Yang Y, Wen YK, Chiu PF. Mean Corpuscular Volume and Mortality in Patients with CKD. Clin J Am Soc Nephrol. 2017;12(2):237-244.
Aldrete S, Jang JH, Easley KA, et al. CD4 rate of increase is preferred to CD4 threshold for predicting outcomes among virologically suppressed HIV-infected adults on antiretroviral therapy. PLoS One. 2020;15(1):e0227124.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
